Top Story Today
The Tariff Threat That Got Pharma Giants to Cut a Deal
Major drugmakers including Pfizer, Novo Nordisk, and AbbVie signed voluntary pricing deals with the Trump administration after facing the threat of tariffs on imported medicines. Novo Nordisk reportedly slashed Wegovy and Ozempic cash prices from about $499 to roughly $349 per month. Sanofi cut Plavix from $756 to $16. But all signatory companies still raised at least some list prices in 2026, and most deal terms remain confidential. The discounts target specific products on the government's TrumpRx.gov portal, not entire portfolios.
Why it matters: If most-favored-nation pricing sticks and expands, it could permanently compress branded drug margins in the U.S. The tariffs are the crowbar; the real shift is in pricing policy trajectory, with smaller firms lacking negotiating leverage facing the steepest risk.
Read more →Clinical and Regulatory
The Cancer That Kills Most Patients in a Year Just Met Its Match
GSK's Hansoh-partnered antibody-drug conjugate hit its primary endpoint in a Phase 3 trial for relapsed small-cell lung cancer, a disease where median survival with second-line therapy is generally well under 12 months. GSK hasn't released actual numbers yet, but the signal validates both the B7-H3 target and a $185 million licensing bet that could unlock a multi-tumor franchise.
Read more →Moderna's Flu-COVID Combo Vaccine Just Made History in Europe
Europe approved the world's first combined flu-COVID vaccine: Moderna's mCOMBRIAX for adults 50 and older. In Phase 3 trials, the single mRNA shot triggered stronger immune responses than getting separate flu and COVID vaccines at the same time. The U.S. path is rockier (Moderna withdrew its FDA application last year and resubmitted), but this cracks open a $10 billion seasonal vaccine market dominated by legacy players.
Read more →A Liver Cancer Drug Still Can't Get Past the FDA, and Not Because It Doesn't Work
The FDA has twice rejected Elevar and Hengrui's liver cancer combo (camrelizumab plus rivoceranib) over manufacturing deficiencies at a Chinese facility, and a resubmission is now under review with a July 2026 PDUFA date. The clinical data is strong: 23.8 months median survival versus 15.2 for the standard. But Hengrui's Suzhou plant keeps failing inspections, putting a potential $1 billion deal at risk while competitors cement their hold on the market.
Read more →France Flags Brain Tumor Risk With Popular Progestin Contraceptives
France's national drug safety agency (ANSM) flagged a small increased risk of meningioma (a usually benign brain tumor) with prolonged use of desogestrel and etonogestrel contraceptives, products used by millions of women including Nexplanon. The risk is roughly one surgery-requiring tumor per 17,000 women exposed for over five years. Label changes are likely coming, and levonorgestrel-based alternatives showed no elevated risk.
Read more →Deals and Business
Apollo Injects 3 Billion Euros Into Bayer (While Bayer Keeps the Keys)
Apollo is injecting 3 billion euros into Bayer in a capital-structure financing transaction. Bayer keeps full operational control while pocketing capital it desperately needs: the company faces roughly 5 billion euros in Roundup litigation payouts this year alone, enough to push it into negative free cash flow.
Read more →Sanofi Wants to Give Myeloma Patients Their Tuesdays Back
Sanofi's subcutaneous Sarclisa via a wearable on-body injector is under FDA review with a PDUFA date of July 23, 2026, and would be the first cancer therapy in the U.S. delivered this way. In trials, infusion reactions dropped from 25% to 1.5% versus IV. It won't dethrone J&J's roughly $14 billion Darzalex franchise overnight, but it could erode the convenience advantage that made Darzalex Faspro the default choice for many doctors.
Read more →Policy and Funding
ARPA-H Bets $160 Million That Gene Therapy Can Work Like a Copy Machine
ARPA-H awarded up to $160 million across seven research teams to build reusable platforms for customized gene therapies. The goal: hold the delivery system constant, swap the genetic instructions per patient. Right now 95% of rare diseases have zero approved treatments, largely because building a bespoke therapy for each one is impossibly expensive. If the platform concept works, that math changes entirely.
Read more →Germany Just Squeezed Pharma Pricing From Every Direction
Germany's parliament passed sweeping drug pricing reforms: higher mandatory rebates, a new dynamic rebate tied to spending growth, extended price freezes through 2030, and a pilot program applying competitive bidding to patented drugs. Because many European countries set prices based on what Germany pays, the ripple effects could compress margins continent-wide.
Read more →